[ad_1] SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 7, 2025 /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics […]
Tag: IASO Bio
IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
[ad_1] SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for […]
IASO Bio Partners with Korea’s GC Cell to Bring CAR-T Therapy to Korea
[ad_1] Potential new treatment option for multiple myeloma patients in Korea. Expanded patient access through competitive pricing. SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ — Nanjing IASO Biotechnology (“IASO Bio”), today […]
JAMA Oncology Publishes Phase 1b/2 Study Data on IASO Bio’s Equecabtagene Autoleucel (Fucaso™) in the Treatment of Relapsed/Refractory Multiple Myeloma
[ad_1] —— The Phase 1b/2 study FUMANBA-1 demonstrates Equecabtagene Autoleucel led to deep and durable responses in patients with R/RMM —— The data shows the overall response rate（ORR）was 96.1%，the ORR reached 98.9% among the patients […]
IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment
[ad_1] SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 30, 2024 /PRNewswire/ — On September 23, in Rio de Janeiro, on the eve of the International Myeloma Society (IMS) Annual Meeting, Dr. Yongke Zhang, Chief […]
